Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
1. A method for reducing risk of liver fibrosis in a human, the method comprising:
a) testing nucleic acid from said human for a polymorphism in gene DDX5 as represented by position 101 of SEQ ID NO:19179 or its complement by contacting said nucleic acid with an allele-specific primer that specifically hybridizes to C at said position 101 of SEQ ID NO:19179 or G at said complement;
b) detecting said C or said G;
c) identifying said human as having an increased risk for liver fibrosis due to the presence of said C or said G; and
d) administering a therapeutic agent suitable for prevention or treatment of liver fibrosis to said human.
2. The method of claim 1 , wherein said allele-specific primer comprises SEQ ID NO:34437 or a sequence fully complementary thereto.
3. The method of claim 1 , wherein said testing comprises allele-specific amplification, and further wherein said detecting comprises detecting the presence of an amplicon.
4. The method of claim 1 , wherein said allele-specific primer is detectably labeled with a fluorescent dye.
5. The method of claim 1 , wherein said human is homozygous for said C or said G.
6. The method of claim 1 , wherein said human is heterozygous for said C or said G.
7. The method claim 1 , wherein said human is infected with hepatitis C virus.
8. A method for reducing risk of liver fibrosis in a human, the method comprising:
a) testing nucleic acid from said human for a polymorphism in gene DDX5 as represented by position 101 of SEQ ID NO:19179 or its complement by contacting said nucleic acid with an oligonucleotide that specifically hybridizes to C at said position 101 of SEQ ID NO:19179 or G at said complement;
b) detecting said C or said G
c) identifying diagnosing said human as having an increased risk for liver fibrosis due to the presence of said C or said G; and
d) administering a therapeutic agent suitable for prevention or treatment of liver fibrosis to said human.
9. The method of claim 8 , wherein said method comprises nucleic acid amplification by polymerase chain reaction (PCR).
10. The method of claim 8 , wherein said oligonucleotide is an allele-specific probe.
11. The method of claim 8 , wherein said oligonucleotide is detectably labeled with a fluorescent dye.
12. The method of claim 8 , wherein said human is homozygous for said C or said G.
13. The method of claim 8 , wherein said human is heterozygous for said C or said G.
14. The method claim 8 , wherein said human is infected with hepatitis C virus.
15. A method for reducing risk of liver fibrosis in a human, the method comprising:
a) receiving an identification of a human as having an increased risk for liver fibrosis due to a polymorphism in gene DDX5 comprising C at position 101 of SEQ ID NO: 19179 or G at its complement; and
b) administering a therapeutic agent suitable for prevention or treatment of liver fibrosis to said human.
16. The method of claim 15 , wherein said human is homozygous for said C or said G.
17. The method of claim 15 , wherein said human is heterozygous for said C or said G.
18. The method claim 15 , wherein said human is infected with hepatitis C virus.